born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. the extraordinary team at nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.
Company profile
Ticker
NAUT
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ARYA Sciences Acquisition Corp III
SEC CIK
NAUT stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
EFFECT
Notice of effectiveness
7 Mar 24
424B5
Prospectus supplement for primary offering
6 Mar 24
8-K
Entry into a Material Definitive Agreement
28 Feb 24
S-3
Shelf registration
28 Feb 24
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results
28 Feb 24
Transcripts
NAUT
Earnings call transcript
2023 Q4
28 Feb 24
NAUT
Earnings call transcript
2023 Q3
31 Oct 23
NAUT
Earnings call transcript
2023 Q2
2 Aug 23
NAUT
Earnings call transcript
2023 Q1
2 May 23
NAUT
Earnings call transcript
2022 Q4
23 Feb 23
NAUT
Earnings call transcript
2022 Q3
1 Nov 22
NAUT
Earnings call transcript
2022 Q2
2 Aug 22
NAUT
Earnings call transcript
2022 Q1
3 May 22
NAUT
Earnings call transcript
2021 Q4
26 Feb 22
NAUT
Earnings call transcript
2021 Q4
24 Feb 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 75.11 mm | 75.11 mm | 75.11 mm | 75.11 mm | 75.11 mm | 75.11 mm |
Cash burn (monthly) | (no burn) | 9.56 mm | 6.36 mm | 6.04 mm | 3.91 mm | 4.02 mm |
Cash used (since last report) | n/a | 65.95 mm | 43.89 mm | 41.67 mm | 27.01 mm | 27.72 mm |
Cash remaining | n/a | 9.15 mm | 31.22 mm | 33.43 mm | 48.10 mm | 47.39 mm |
Runway (months of cash) | n/a | 1.0 | 4.9 | 5.5 | 12.3 | 11.8 |
Institutional ownership, Q3 2023
58.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 76 |
Opened positions | 4 |
Closed positions | 4 |
Increased positions | 25 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 123.08 bn |
Total shares | 72.67 mm |
Total puts | 100.00 |
Total calls | 16.70 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
AH Bio Fund II | 16.30 mm | $0.00 |
Perceptive Advisors | 9.11 mm | $28.79 bn |
VCVC V | 7.17 mm | $37.16 mm |
Cercano Management | 7.17 mm | $22.67 bn |
Madrona Venture | 6.02 mm | $19.03 mm |
Sciences Holdings ARYA III | 4.15 mm | $0.00 |
BLK Blackrock | 3.74 mm | $11.81 bn |
Vanguard | 2.81 mm | $8.87 bn |
Comprehensive Financial Management | 2.21 mm | $6.98 bn |
Bain Capital Life Sciences Investors | 2.00 mm | $6.32 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Mar 24 | Sujal M Patel | Common Stock | Buy | Acquire P | No | No | 2.8409 | 12,044 | 34.22 k | 10,064,488 |
8 Mar 24 | Sujal M Patel | Common Stock | Buy | Acquire P | No | No | 2.9885 | 2,430 | 7.26 k | 10,052,444 |
7 Mar 24 | Sujal M Patel | Common Stock | Buy | Acquire P | No | No | 2.8866 | 18,854 | 54.42 k | 10,050,014 |
6 Mar 24 | Sujal M Patel | Common Stock | Buy | Acquire P | No | No | 2.7014 | 9,267 | 25.03 k | 10,031,160 |
5 Mar 24 | Sujal M Patel | Common Stock | Buy | Acquire P | No | No | 2.6464 | 7,405 | 19.60 k | 10,021,893 |
1 Mar 24 | Sujal M Patel | Stock Option Common Stock | Grant | Acquire A | No | No | 2.72 | 650,000 | 1.77 mm | 650,000 |
1 Mar 24 | Parag Mallick | Stock Option Common Stock | Grant | Acquire A | No | No | 2.72 | 280,000 | 761.60 k | 280,000 |
1 Mar 24 | Nicholas A. Nelson | Stock Option Common Stock | Grant | Acquire A | No | No | 2.72 | 160,000 | 435.20 k | 160,000 |